AVITA Medical (RCEL) Short term Debt (2025 - 2026)

AVITA Medical's (RCEL) quarterly Short term Debt came in at $43.0 million in Q4 2025, up 1332.8% on a QoQ basis from $3.0 million in Q3 2025.

AVITA Medical (RCEL) Short term Debt (2025 - 2026) Analysis & Trends

AVITA Medical (RCEL) has 1 years of Short term Debt data on file, last reported at $43.0 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $43.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $43.0 million (changed N/A YoY) and the FY2025 annual result came in at $43.0 million, changed N/A from the prior year.
Short term Debt rose to $43.0 million in Q4 2025, from $3.0 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $43.0 million in Q4 2025 to a low of $3.0 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.49 Bn	193.88 Bn	7.27 Bn
2	Stryker	127.80 Bn	124.32 Bn	4.50 Bn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn
4	Boston Scientific	73.58 Bn	73.04 Bn	3.85 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn
6	Dexcom	34.34 Bn	32.39 Bn	830.00 Mn
7	GE HealthCare Technologies	33.76 Bn	31.66 Bn	2.18 Bn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn
9	Steris	23.07 Bn	22.59 Bn	684.20 Mn
10	AVITA Medical	311.80 Mn	300.67 Mn	17.77 Mn

Download Data